Navigation Links
Hillenbrand, Inc. Declares First Quarterly Dividend As a New Publicly Traded Company
Date:4/30/2008

BATESVILLE, Ind., April 30 /PRNewswire-FirstCall/ -- Hillenbrand, Inc. (NYSE: HI) today announced that its Board of Directors declared the company's first dividend as a publicly traded company of $0.1825 per share on the company's common stock. The dividend is payable June 30, 2008 to shareholders of record at the close of business on June 16, 2008.

"The decision by our board to approve this inaugural dividend is based on the strength of our fundamentals, including strong and consistent cashflows, and demonstrates our long-term commitment to creating and increasing shareholder value," said Hillenbrand's President and CEO, Kenneth A. Camp.

ABOUT HILLENBRAND, INC.

Hillenbrand, Inc. is the holding company for Batesville Casket Company, a leader in the North American death care industry through the sale of funeral services products, including burial caskets, cremation caskets, containers and urns, selection room display fixturing and other personalization and memorialization products.

Batesville Casket Company ... helping families honor the lives of those they love.

http://www.hillenbrandinc.com

Certain statements in this release contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, regarding the future plans, objectives, beliefs, expectations, representations, and projections of Hillenbrand, Inc. (the "Company"). The Company has tried, wherever possible, to identify these forward looking statements using words such as "intend," "anticipate," "believe," "plan," "expect," "may," "goal," "become," "pursue," "estimate," "strategy," "will," "projection," "forecast," "continue," "accelerate," "promise," "increase," "higher," "lower," "reduce," "improve," "expand," "progress," "potential" or the negative of those terms, other variations of them, or by comparable terminology. The absence of such terms, however, does not mean that the statement is not forward looking. It is important to note that forward looking statements are not guarantees of future performance, and the Company's actual results could differ materially from those set forth in any forward looking statements. Factors that could cause actual results to differ from forward looking statements include, but are not limited to: the antitrust litigation in which the Company is currently a defendant; the Company's dependence on its relationships with several large national providers; continued fluctuations in mortality rates and increased cremations; ongoing involvement in claims, lawsuits, and governmental proceedings; failure of the Company's announced strategic initiatives to achieve expected growth, efficiencies, or cost reductions; disruptions in the Company's business or other adverse consequences resulting from the spin-off of the Company from Hillenbrand Industries, Inc.; competition from nontraditional sources in the funeral service business; increased costs or unavailability of raw materials; labor disruptions; the ability to retain executive officers and other key personnel; and certain tax-related matters. For a more in depth discussion of these and other factors that could cause actual results to differ from those contained in forward looking statements, see the discussions under the heading "Risk Factors" in the Information Statement dated March 17, 2008 filed as Exhibit 99.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 17, 2008. The Company assumes no obligation to update or revise any forward looking statements.


'/>"/>
SOURCE Hillenbrand, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Torchmark Corporation Declares Dividend
3. Aflac Incorporated Announces First Quarter Results, Declares Second Quarter Cash Dividend
4. STERIS Corporation Declares Regular Quarterly Dividend
5. State Legislature Declares April 21 to 25, 2008 West Nile Virus and Mosquito and Vector Control Awareness Week
6. Lilly Declares Second-Quarter Dividend
7. Otter Tail Corporation Holds 2008 Annual Meeting: Shareholders Elect Directors; Board Declares Quarterly Dividend
8. NCPA Declares April 14 - 18 Protect Your Pharmacy Week
9. P&G Declares a 14% Dividend Increase
10. Coalition to Prevent Deep-Vein Thrombosis (DVT) Turns Awareness Into Action as it Declares First-Of-Its-Kind National DVT Screening Day
11. Birner Dental Management Services, Inc. Declares $.17 Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: